Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02005601 · ClinicalTrials.gov registry record · Phase 4

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

A Phase 4 study of Total Knee Arthroplasty, sponsored by Hospital for Special Surgery, New York.

Completed
Registry status
Phase 4
Development phase
106
Enrollment target
1
Study location

NCT02005601 is a Phase 4 study of Total Knee Arthroplasty that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 106 participants, below the 291-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02005601, a Phase 4 study of Total Knee Arthroplasty, has completed, sponsored by Hospital for Special Surgery, New York.

COMPLETED
Registry status
Phase 4
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

We are investigating the impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor, on pain after total knee arthroplasty (TKA). Specifically, the investigators will determine whether duloxetine, 60 mg daily for 2 weeks, reduces pain scores 2 weeks after TKA.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Duloxetine 60mg

Study Locations (1)

New York

  • Hospital for Special Surgery - New York

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2013-11
Est. Completion 2015-08
Phase Phase 4

What the Registry Record Tells You About NCT02005601

The ClinicalTrials.gov registry entry for NCT02005601 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 291-participant average among 29 other Total Knee Arthroplasty trials with a reported enrollment target (64% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Total Knee Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02005601 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02005601 about?

NCT02005601 is a clinical study titled "Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?". We are investigating the impact of duloxetine ("Cymbalta"), a serotonin and norepinephrine reuptake inhibitor, on pain after total knee arthroplasty (TKA). Specifically, the investigators will determine whether duloxetine, 60 mg daily for 2 weeks, reduces pain scores 2 weeks after TKA.

What is the current status of trial NCT02005601?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2013-11. Estimated completion is 2015-08.

What conditions does trial NCT02005601 study?

This clinical trial studies the following conditions: Total Knee Arthroplasty.

What interventions are being tested in trial NCT02005601?

The interventions under investigation include: Placebo (DRUG), Duloxetine 60mg (DRUG).

Who is sponsoring clinical trial NCT02005601?

This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02005601 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Total Knee Arthroplasty

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.